<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01470131</url>
  </required_header>
  <id_info>
    <org_study_id>AB06002</org_study_id>
    <nct_id>NCT01470131</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma</brief_title>
  <official_title>A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled, 2-parallel Group, Phase 3 Study to Compare Efficacy and Safety of Masitinib 6 mg/kg/Day in Combination With Bortezomib and Dexamethasone to Placebo in Combination With Bortezomib and Dexamethasone in the Treatment of Patients With Relapsing Multiple Myeloma Who Received One Previous Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AB Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AB Science</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the efficacy and safety of masitinib 6 mg/kg/day in
      combination with bortezomib and dexamethasone to placebo in combination with bortezomib and
      dexamethasone in the treatment of patients with relapsing multiple myeloma who have received
      one previous therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel
      group, phase 3 study to compare efficacy and safety of masitinib 9 mg/kg/day to placebo in
      the treatment of patients with relapsing multiple myeloma who received one previous therapy.

      Patients will receive study treatment (masitinib/placebo) with the standard therapy
      (bortezomib and dexamethazone).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Analysis to be conducted after a minimum of 201 events</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Time to Progression</measure>
    <time_frame>time from the date of randomization to the date of documented progression during the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Until death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>masitinib 6 mg/kg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>masitinib in combination with Bortezomib and Dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo in combination with Bortezomib and Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>masitinib 6 mg/kg/day</intervention_name>
    <description>masitinib 6 mg/kg/day</description>
    <arm_group_label>masitinib 6 mg/kg/day</arm_group_label>
    <other_name>masitinib 6 mg/kg/day with Bortezomib &amp; Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo in combination with Bortezomib and Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient with confirmed multiple myeloma requiring systemic therapy. All three criteria
             must be met:

               -  Clonal bone marrow plasma cells &gt; 10%

               -  Presence of serum and/or urinary monoclonal protein

               -  Evidence of end-organ damage that can be attributed to the underlying plasma cell
                  proliferative disorder, specifically:

                    -  Hypercalcemia: serum calcium &gt; 11.5 mg/100 ml or

                    -  Renal insufficiency: serum creatinine &gt; 173 µmol/l

                    -  Anemia: normochromic, normocytic with a hemoglobin value of &gt; 2g/100 ml
                       below the lower limit of normal or a hemoglobin value &lt; 10g/100 ml

                    -  Bone lesions: lytic lesions, severe osteopenia or pathologic fractures

          2. Patient with multiple myeloma relapsing according to the International uniform
             response criteria for multiple myeloma (IMWG 2009/ revised Bladé criteria) to one
             previous line of treatment

          3. Patient with measurable progressive disease defined by at least one of the following
             two measurements:

               -  Serum M-protein ≥ 1 g/dL

               -  Urine M-protein ≥ 200 mg/24h

        Exclusion Criteria:

          1. Patient with peripheral neuropathy Grade &gt;2

          2. Patient with hypersensitivity to bortezomib, boron or dexamethasone

          3. Patient whose disease progressed during or within 60 days of bortezomib treatment or
             of any other Multiple Myeloma therapy

          4. Patient who received bortezomib within 6 months of randomization to this study

          5. Past discontinuation of bortezomib due to associated grade 3 or higher adverse event

          6. Patient with contra-indication to high dose of steroids (including ongoing active
             infection, use of live vaccines, virosis such as hepatitis, herpes, varicella, herpes
             zoster)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertrand Arnulf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Saint-Louis, Paris - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bertrand Arnulf, MD</last_name>
    <email>bertrand.arnulf@sls.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical and Surgical Specialists</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeastern Medical Oncology Center</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Froedtert &amp; Medical College of Wisconsin-CLCC</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud Francilien</name>
      <address>
        <city>Corbeil Essonne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CH Le Mans</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Saint Jean</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>November 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2011</study_first_posted>
  <last_update_submitted>December 12, 2012</last_update_submitted>
  <last_update_submitted_qc>December 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>relapse</keyword>
  <keyword>second line therapy</keyword>
  <keyword>bortezomib</keyword>
  <keyword>dexamethasone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

